Apixaban

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Deep-Vein Thrombosis

Conditions

Deep-Vein Thrombosis

Trial Timeline

Nov 1, 2005 → Feb 1, 2007

NCT ID

NCT00252005

About Apixaban

Apixaban is a phase 2 stage product being developed by Bristol Myers Squibb for Deep-Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00252005. Target conditions include Deep-Vein Thrombosis.

What happened to similar drugs?

1 of 1 similar drugs in Deep-Vein Thrombosis were approved

Approved (1) Terminated (0) Active (0)

✅Dalteparin sodium injection + WarfarinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05187286	Pre-clinical	Active	—	—	—
NCT03594045	Phase 2	Terminated	Dec 18, 2018	Oct 30, 2019	Heparin-induced Thrombocytopenia
NCT02958969	Approved	Completed	Feb 28, 2018	Nov 19, 2019	Venous Thromboembolism
NCT03456648	Phase 2	Completed	Sep 25, 2016	Aug 24, 2018	ESRD
NCT02714855	Pre-clinical	Completed	Oct 1, 2015	Dec 1, 2016	Anticoagulation
NCT02345343	Pre-clinical	Completed	May 4, 2015	Oct 7, 2015	Deep Vein Thrombosis
NCT01885585	Pre-clinical	Completed	Jul 1, 2014	May 1, 2015	Venous Thromboembolism
NCT02153424	Pre-clinical	Withdrawn	Apr 1, 2014	Nov 1, 2015	Non-valvular Atrial Fibrillation (NVAF)
NCT02101112	Phase 1	Completed	Mar 1, 2014	May 1, 2014	Thrombosis
NCT01884350	Approved	Completed	Oct 15, 2013	Jan 20, 2016	Non-valvular Atrial Fibrillation
NCT01885598	Pre-clinical	Completed	Jul 10, 2013	Sep 29, 2017	NonValvular Atrial Fibrillation
NCT00252005	Phase 2	Completed	Nov 1, 2005	Feb 1, 2007	Deep-Vein Thrombosis

Competing Products

1 competing product in Deep-Vein Thrombosis

See all competitors

Product	Company	Stage	Hype Score
Dalteparin sodium injection + Warfarin	Pfizer	Approved	43